Labcorp to offer HPV and STI self-collection solutions

Labcorp (LH) will offer nationwide an FDA-approved human papillomavirus self-collection solution that can help women and their physicians asses the risk of developing cervical cancer. Labcorp will also offer a vaginal swab self-collect option for sexually transmitted infection testing. Both solutions are available by physician order and can be completed privately in a healthcare setting or at any one of Labcorp’s 2,200 Patient Service Centers nationwide. In 2024, the FDA approved self-collection tests for cervical cancer screenings. Labcorp will also offer a vaginal swab self-collect option for STI testing, including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium.